EXELIXIS INC (EXEL)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for EXEL
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| EXEL | Independent Director | 71 | ["Training as a scientist","Knowledge and experience in U.S. and global public health","Experience in the biopharmaceutical industry and government healthcare policymaking","Leadership experience in the public sector","Former President and Executive Director, Foundation for the National Institutes of Health","Former President and member of the board of directors of the Albert and Mary Lasker Foundation","Former President and CEO of the TB Alliance","Director of the Office of Technology Transfer at the National Institutes of Health"] | ["Governance Committee","Research & Development Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| BIIB | Independent Chair (after 2026 Annual Meeting) | 71 | ["Executive Leadership and Business Operations","Drug Development","Healthcare and Pharma Leadership","Finance and Accounting","International Business","Public Board Service","Government and Public Policy","Medicine and Scientific Research","Significant knowledge and experience with respect to medical research","Expertise in pharmaceutical industry and government healthcare policymaking","Strong public policy and government experience"] | ["Compensation and Management Development","Corporate Governance"] | 2026 |
| ARE | Prior President and Executive Director of Foundation for the National Institutes of Health (“FNIH”); Founder and Principal of The Freire Group; Chair of the Board of Directors | 71 | ["Founder and Principal of The Freire Group", "senior life sciences executive", "expertise in drug development", "biomedical innovation", "technology commercialization", "science policy", "Former President and Executive Director of the FNIH", "Former President and CEO of the TB Alliance", "Directed the Office of Technology Transfer at NIH"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Maria C. Freire, Ph.D., has been a director since April 2018. From 2012 to 2021, Dr. Freire served as President and Executive Director of the Foundation for the National Institutes of Health, and as a member of its board of directors, where she supported public private partnerships advancing research and clinical trials across oncology, neurodegenerative disease, autoimmune disorders and infectious diseases. From 2008 to 2012, she served as President, and a member of the board of directors, of the Albert and Mary Lasker Foundation, which awards the Lasker Awards in basic and clinical science. From 2001 to 2008, Dr. Freire served as President and Chief Executive Officer of the TB Alliance, where she led drug-development efforts, including the advancement of Pretomanid from preclinical to clinical trials; Pretomanid is now approved for treatment of multidrug-resistant tuberculosis (MDR-TB). From 1995 to 2001, Dr. Freire was Director of the Office of Technology Transfer at the National Institutes of Health. Dr. Freire serves on the board of directors of: Biogen Inc., a publicly held biopharmaceutical company focused on the treatment of serious diseases, since 2021, and in February 2026 was elected Chair of the Biogen board of directors, effective following Biogen's 2025 Annual Shareholders Meeting in June 2026; and Alexandria Real Estate Equities, Inc., a publicly held urban office real estate investment trust focused on collaborative life science and technology campuses, since 2012. She has also held national and international leadership roles, including Chair of the Science Board of the U.S. Food and Drug Administration, member of the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health and member of the United Nations Secretary General's High-Level Panel on Access to Medicines. Dr. Freire is also a member of the National Academy of Medicine and the Council on Foreign Relations, and has received several honors, including the 2017 Gold Stevie Award for Woman of the Year, the U.S. Department of Health and Human Services Secretary's Award for Distinguished Service, the Arthur S. Fleming Award and the Bayh-Dole Award. Dr. Freire holds a Ph.D. in Biophysics from the University of Virginia and a B.S. from the Universidad Peruana Cayetano Heredia in Lima, Peru.